Abstract
Abstract
Hemorrhagic shock remains a major cause of potentially preventable death after trauma, and early assessment of its severity is essential. This prospective observational biomarker study evaluated admission serum copeptin in 103 adult trauma patients. The primary analysis compared hemorrhagic shock stage 1 (n = 73) with stage ≥ 2 (n = 30). Median copeptin was 602.4 pg/mL (Q1–Q3, 519.3–646.6) in stage 1 and 679.5 pg/mL (650.5–744.3) in stage ≥ 2 (Mann–Whitney U = 371.5,
p
p
= 0.050). Admission copeptin was associated with hemorrhagic shock severity, but the data-derived threshold and borderline adjusted association require external validation. Copeptin should be considered an exploratory adjunct rather than a standalone decision tool.